Company: MYSEW
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001213900-25-044159
Chunk: 31

Company: Myseum, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Part I, Item 1
Chunk 31
---
6, 2022 and a prospectus supplement dated January 8, 2025.
The closing of the sales of these securities under the Purchase Agreement took place on January 9, 2025 and the Company received net proceeds
of $4,532,000 after deducting placement fees and expenses of $568,000. The Company intends to use the net proceeds from the offering for
working capital and other general corporate purposes.

On January 7, 2025, the Company entered into an
engagement agreement with The Benchmark Company, LLC, as exclusive placement agent (“Benchmark” or the “Placement Agent”),
pursuant to which the Placement Agent agreed to act as placement agent on a reasonable “best efforts” basis in connection
with the Offering. The Company agreed to pay the Placement Agent an aggregate cash fee equal to 7.0% of the gross proceeds from the sale
of securities in the Offering and a non-accountable expense allowance equal to 1.0% of the gross proceeds raised in the Offering. The
Company also agreed to issue the Placement Agent (or its designees) a warrant (the “Placement Agent Warrant”) to
purchase up to 5% of the aggregate number of shares of Common Stock sold in the offering, or warrants to purchase up to 60,000 shares
of Common Stock, at an exercise price equal to 100.0% of the offering price per share of Common Stock, or $4.25 per share. The Placement
Agent Warrant is exercisable during the four-and-a-half year period commencing six months after the date of the closing of this Offering.
In addition, the Company agreed to pay the Placement Agent $80,000 for legal expenses and other out-of-pocket expenses.

Equity Sales Agreement

On February 10, 2025, the Company entered into
a Sales Agreement (the “Sales Agreement”) with The Benchmark Company, LLC (“Benchmark”) to sell shares of the
Company’s common shares (the “Shares”) having an aggregate sales price of up to $6,000,000, from time to time, through
an “at the market offering” program under which Benchmark will act as sales agent. The sales, if any, of the Shares made under
the Sales Agreement will be made by any method permitted by law deemed to be an “at the market offering” as defined in Rule
415 promulgated under the Securities Act of 1933, as amended.

The Company will